Musa Tariq Sells 2,320 Shares of Guardant Health, Inc. (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) Director Musa Tariq sold 2,320 shares of the company’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the sale, the director now owns 2,676 shares of the company’s stock, valued at approximately $93,660. This represents a 46.44 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Guardant Health Trading Down 2.2 %

Shares of NASDAQ:GH opened at $34.84 on Wednesday. The company has a quick ratio of 5.85, a current ratio of 6.22 and a debt-to-equity ratio of 16.70. Guardant Health, Inc. has a 52-week low of $15.81 and a 52-week high of $38.53. The stock has a market cap of $4.30 billion, a price-to-earnings ratio of -8.22 and a beta of 1.26. The business has a 50-day moving average price of $28.21 and a 200-day moving average price of $28.21.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.33). The business had revenue of $191.48 million for the quarter, compared to analysts’ expectations of $170.49 million. Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The business’s quarterly revenue was up 33.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.73) earnings per share. Equities analysts predict that Guardant Health, Inc. will post -3.44 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. UBS Group upped their price objective on Guardant Health from $32.00 to $40.00 and gave the stock a “buy” rating in a research note on Wednesday, August 21st. JPMorgan Chase & Co. boosted their target price on shares of Guardant Health from $48.00 to $50.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. The Goldman Sachs Group lifted their price objective on shares of Guardant Health from $32.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Sanford C. Bernstein reduced their price objective on shares of Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a research note on Wednesday, October 30th. Finally, Leerink Partners lowered their target price on shares of Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. Fifteen investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $40.60.

Institutional Investors Weigh In On Guardant Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Cerity Partners LLC lifted its holdings in shares of Guardant Health by 54.6% in the 3rd quarter. Cerity Partners LLC now owns 195,008 shares of the company’s stock valued at $4,473,000 after buying an additional 68,883 shares during the period. Lord Abbett & CO. LLC purchased a new position in Guardant Health during the third quarter valued at approximately $15,624,000. Sumitomo Mitsui Trust Group Inc. lifted its holdings in Guardant Health by 1,282.5% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,226,176 shares of the company’s stock valued at $28,128,000 after acquiring an additional 1,137,482 shares during the period. First Light Asset Management LLC lifted its holdings in Guardant Health by 119.7% in the second quarter. First Light Asset Management LLC now owns 416,967 shares of the company’s stock valued at $12,042,000 after acquiring an additional 227,202 shares during the period. Finally, Pier Capital LLC boosted its position in Guardant Health by 36.7% in the 3rd quarter. Pier Capital LLC now owns 158,429 shares of the company’s stock worth $3,634,000 after purchasing an additional 42,575 shares in the last quarter. 92.60% of the stock is owned by institutional investors and hedge funds.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.